Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AR882 in Renal Impairment
NCT04646889Phase 1Completed
- Sponsor
- Arthrosi Therapeutics
- Start
- Jan 2021
- Primary completion
- Jun 2022
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label trial of pozdeutinurad in gout and hyperuricemia (2 arms), sponsored by Arthrosi Therapeutics. Primary endpoints: Area under the curve for plasma following a single dose of AR882 at 6 days, Maximum plasma concentration following a single dose of AR882 at 6 days and 6 more. Started Jan 2021; status: completed.
02
Drugs
pozdeutinurad
03
Conditions
gouthyperuricemia
Beyond the preview
Go deeper on NCT04646889.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04646889.